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_______________________________________________
Meghan A. Cooper 1, Rafael E. Carrion 2, Christopher Yang 2
Lake Erie College of Osteopathic Medicine, Bradenton, Florida, USA; 2 Department of Urology, University
of South Florida Morsani College of Medicine, Tampa, Florida, USA

1

ABSTRACT									ARTICLE INFO
______________________________________________________________

______________________

Main findings: A 26-year-old man suffering from partial priapism was successfully
treated with a regimen including pentoxifylline, a nonspecific phosphodiesterase inhibitor that is often used to conservatively treat Peyronie’s disease.
Case hypothesis: Partial priapism is an extremely rare urological condition that is characterized by thrombosis within the proximal segment of a single corpus cavernosum.
There have only been 36 reported cases to date. Although several factors have been
associated with this unusual disorder, such as trauma or bicycle riding, the etiology
is still not completely understood. Treatment is usually conservative and consists of a
non-steroidal anti-inflammatory and anti-thrombotic.
Promising future implications: This case report supports the utilization of pentoxifylline in patients with partial priapism due to its anti-fibrogenic and anti-thrombotic
properties.
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SCENARIO
A 26-year-old man presented to the emergency department with severe, right-sided perineal pain of 24 hours duration. He described the pain
as non-radiating and sharp, denied any trauma,
but did have mild dysuria. The patient had chlamydial urethritis one year ago that was successfully treated with oral antibiotics. His last reported
sexual encounter was three months ago, and he
was an avid bicycle motocross rider. He denied
tobacco or marijuana use, but did use alcohol several hours prior to initial presentation of pain.
Physical examination was remarkable only for a
2cm tender area of firm induration on the right
aspect of the perineum.

Complete blood count, comprehensive metabolic panel, and urinalysis were unremarkable,
with the exception of urinary nitrites and urine
urobilinogen of 2.0mg/dL. Computed tomography
(CT) of the pelvis showed asymmetric enlargement
of the proximal right corpus cavernosum with an
area of thin hyperdense tissue distal to the enlarged region (Figure-1A). The patient was evaluated
by a urology resident, discussed with an attending
urologist, and discharged with ciprofloxacin for
presumed urinary tract infection.
Three days later he returned to the hospital with worsening right-sided perineal pain. In the
interim he had erections that exacerbated the pain,
and detumescence did not result in resolution of the
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pain or perineal swelling. Physical examination
was unchanged. Repeat laboratory tests showed
normalization of all parameters. Repeat CT showed the same picture, with a hyperdense membrane distal to the right proximal corporal thrombosis
(Figure-1B). He was evaluated by a different urology resident and attending physician, and diagnosed with partial priapism. He was discharged with
conservative treatment of ibuprofen 800mg three
times daily, acetylsalicylic acid 325mg daily, and
pentoxifylline 400mg twice daily.
At follow-up two days later he had significantly decreased pain, though still had right
proximal cavernosal swelling and tenderness to
palpation. The pain and perineal swelling completely resolved over the course of one month.
He stopped taking the prescribed medications six
weeks after initial presentation. At last follow-up
three months after initial presentation, the patient
reported continued resolution of perineal swelling,
no impairment of erectile function and no further
episodes of partial priapism.
Figure 1 - Computed tomography image of patient with
partial priapism of the proximal right corpus cavernosum. A)
Initial imaging at first presentation to the emergency room;
B) Imaging three days later showing well-defined transverse
membrane separating the proximal thrombosed and distal
non-thrombosed sections of right corpus cavernosum.
A

B

Case hypothesis and rationale
Partial priapism is a rare non-emergent
condition first reported in 1976 (1, 2). The typical
presentation is a young man with a firm, painful
perineal mass sometimes accompanied by erectile dysfunction, penile pain, dysuria, or decreased
urinary flow (3, 4). Several factors have been associated with partial priapism, including bicycle

riding, trauma, prolonged or vigorous intercourse, hematologic disorders, history of prostatitis
or hepatitis A, marijuana and cocaine abuse, use
of tamsulosin or sildenafil, recent airplane flight,
prior priapism, and fever of unknown origin (3, 4).
Initial treatment for partial priapism is conservative, consisting of non-steroidal anti-inflammatory
drugs (NSAIDs), acetylsalicylic acid, heparin, or
low molecular weight heparin. In cases not responding to conservative therapy, surgical intervention is required (3-5).
This report describes the first known usage
of pentoxifylline (PTX) in the treatment of partial
priapism. This also highlights the need for greater
awareness of partial priapism as a formal pathologic entity in the medical community.
Discussion and future perspectives
Partial priapism is an uncommon condition characterized by thrombosis within the proximal segment of the corpus cavernosum. There
have been only 36 cases reported previously in
the world literature (4, 6). The initial cases of partial priapism were treated surgically with corporotomy and clot evacuation that led to a high rate of
recurrence and erectile dysfunction (7). Recently
most cases are treated conservatively with NSAIDs,
acetylsalicylic acid, and/or anticoagulants (3, 4, 8).
The etiology of this condition remains
elusive. Ilicki and colleagues proposed a two-hit
model to explain the mechanism of partial segmental thrombosis in which a permeable transverse membrane divides the corpus cavernosum
into a proximal and distal portion. This membrane
can be either congenital or posttraumatic. Secondly, there must be a triggering event, often trauma
to the penis, which blocks the permeable parts of
the membrane. With tumescence the intracorporal
blood can form clot, which impedes the membrane
even more. This results in thrombosis of the proximal corpus cavernosum, thereby causing partial
priapism (3).
This model suggests a role for PTX in the
treatment of partial priapism. PTX is a nonspecific
phosphodiesterase inhibitor that has been used in a
variety of fibrotic conditions, including Peyronie’s
disease (PD), radiation proctitis, radiation-induced
fibrosis, alcoholic hepatitis, steatohepatitis, cystic
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fibrosis, radiation pneumonitis, epidural fibrosis,
osteo-radionecrosis, and to prevent atherosclerosis
in hypertensive patients with type 2 diabetes mellitus (9, 10). The role of PTX as an anti-fibrotic is
familiar to urologists in its use in the treatment of
PD, where it has been shown to potentially decrease penile curvature and plaque volume through
its inhibitory effects on fibrogenesis (9-11). As a
nonselective phosphodiesterase inhibitor, PTX decreases tumor necrosis factor-alpha release and nuclear factor-kappa-B transcription, thereby decreasing collagen production (11). PTX also attenuates
transforming growth factor-beta, which has been
implicated in the pathogenesis of numerous human
fibrotic disorders, through its role in stimulating
collagen deposition and mediating plaque formation (11).
PTX has also been investigated in the
treatment of erectile dysfunction (12). Pathologically, the loss of corporal smooth muscle cells
and excess collagen deposition can lead to erectile dysfunction (13). PTX up-regulates nitric
oxide, which leads to the destruction of reactive
oxygen species, thereby mitigating tissue inflammation and fibrosis. In addition, PTX can improve blood flow by decreasing viscosity, increasing
red blood cell flexibility and inhibiting thrombocyte aggregation (12, 13).
For patients with partial priapism, PTX may
be a treatment option due to its effect on both components of Ilicki’s two-hit theory. The anti-fibrotic
properties of PTX may improve the permeability of
the intracorporal membrane, and the improvement
in blood flow and inhibited thrombocyte aggregation may improve flow through the membrane.
The present patient had a transverse membrane separating the thrombosed and non-thrombosed sections of the proximal right corpus cavernosum (Figure-1). He was treated with the most
commonly-described conservative management
(NSAIDs and acetylsalicylic acid), as well as PTX.
It is unknown whether the addition of PTX to the
previously-described regimen hastened or hindered
his return to normal function. However, as he returned to full function within one month of initiation
of treatment, it is unlikely that PTX significantly
worsened his recovery. Further investigation would
be beneficial for verification of the efficacy of PTX

in partial priapism, but the extreme scarcity of patients presenting with this condition precludes randomized controlled trials.
Finally, the management of our patient was
less than ideal due to lack of recognition of the
disease. He presented to the emergency room in
two separate times within a three day span and was
evaluated by our urology service each time. As he
had some symptoms and laboratory abnormalities
similar to urinary tract infection, he was discharged
after the first evaluation with antibiotics despite CT
showing the pathognomonic picture of partial priapism. Prior to this case, none of the urologists at
our institution had ever treated a case of partial
priapism. With this patient being only the 37th reported case of the disease, it is likely that the vast
majority of urologists have never treated or even
have knowledge of this disease. With this and additional reports, it is our hope that physicians will
recognize partial priapism with higher diagnostic
acumen.
In conclusion, partial priapism is a rare,
non-emergent urological condition that is typically
treated conservatively with NSAIDs and acetylsalicylic acid. This is the first case where PTX was
added to the conventional treatment regimen, with
excellent clinical response. Though further investigation is required to verify efficacy, in the rare case
of partial priapism the use of PTX may be considered.
Abbreviations
CT = computed tomography
NSAIDs = non-steroidal anti-inflammatory drugs
PD = Peyronie’s disease
PTX = pentoxifylline
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